Abstract: The present disclose includes, among other things, methods of preparing compound (R)-11. or a pharmaceutically acceptable salt thereof. Compound (R)-11 is useful to treat or lessen the severity of cancer.

Abstract: The present disclose includes, among other things, compounds of formula (I) that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.

Abstract: A hydrochloride salt of inupadenant, pharmaceutical compositions thereof, methods of making pharmaceutical compositions of a hydrochloride salt of inupadenant (e.g., crystalline hydrochloride salt of inupadenant) and methods of using the pharmaceutical compositions in combination with carboplatin and pemetrexed in the treatment of non-small cell lung cancer (NSCLC), including squamous NSCLC and nonsquamous NSCLC.

Abstract: In some embodiments, the present disclosure relates to multicomponent complexes, such as salts, of Compound 1, and hydrates and solvates thereof. In some embodiments, the present disclosure relates to pharmaceutically acceptable salts of Compound 1, and hydrates and solvates thereof. In some embodiments, the present disclosure relates to crystalline complexes comprising Compound 1 (free base) and a coformer, and hydrates and solvates thereof. In some embodiments, the present disclosure relates to a crystalline salt of Compound 1 comprising Compound 1 (free base) and a salt coformer, and hydrates and solvates thereof. In some embodiments, the present disclosure relates to crystalline forms of Compound 1 (free base), and hydrates and solvates thereof. In some embodiments, the present disclosure relates to compositions, dosage forms, and kits comprising a multicomponent complex as disclosed herein.

Abstract: The present disclosure relates to treatment of a subject who has been identified with an increased A2A expression or density of A2AR+ cells.

Abstract: The present disclosure relates to synthesis of enantiomerically rich key drug intermediates as a means for manufacturing of thiocarbamate derivatives as A2A adenosine receptor (A2AR) inhibitors. More particularly, the present disclosure provides a viable efficient technology using enzymatic biotransformation process which utilizes cheaper substrate for production of high value key intermediates for A2AR inhibitors.

Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of Formula (I) for the treatment and/or prevention of proliferative disorders, including cancers.

Abstract: The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-?-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.